ArticleInternational journal of retina and vitreous2025
Real-world short-term outcomes after switching to fixed-interval anti-VEGF therapy for neovascular AMD during the COVID-19 pandemic.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal fluid segmentation in real-world OCT imaging of neovascular AMD using hybrid deep learning and graph-based optimization.Biomedical optics express · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo assess short-term real-world visual and anatomic outcomes in patients with neovascular age-related macular degeneration (nvAMD) following a protocol shift from an individualized treat-and-extend (T&E) anti-VEGF regimen to a fixed-interval injection schedule without routine imaging during the early COVID-19 pandemic.
methodsThis retrospective cohort study included patients with nvAMD undergoing anti-VEGF therapy at a single tertiary academic retina practice. In response to the COVID-19 pandemic, the clinic transitioned from a T&E approach to a fixed 8-week injection schedule without routine OCT imaging between March 25 and July 1, 2020. Eyes with at least two visits and OCT imaging before and after the protocol change were included. Outcomes measured included visual acuity (VA), central macular thickness (CMT), fluid status, appointment adherence, COVID-19 cases, and mortality. Statistical comparisons were performed using paired t-tests and Wilcoxon signed-rank tests.
resultsA total of 289 eyes (232 patients) were included. Mean VA before the switch was 20/45 (logMAR 0.35 ± 0.33) and 20/50 (logMAR 0.39 ± 0.33, p = 0.17) after the switch. Mean CMT showed non-significant changes from 292.1 ± 89 μm pre-switch to 298.7 ± 66 μm (p = 0.15) post-switch. COVID-19 affected 11 patients (6 deaths); no cases were linked to clinic visits, and staff remained unaffected.
conclusionsSwitching to fixed-interval injections with limited imaging effectively maintained visual and anatomical outcomes while safely reducing COVID-19 transmission risks. These results suggest that fixed-interval regimens may preserve short-term outcomes in established nvAMD patients and could be useful during future care disruptions or protocol changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.